Cargando…

Safety, Tolerability, and Pharmacokinetics of Zagotenemab in Participants with Symptomatic Alzheimer’s Disease: A Phase I Clinical Trial

BACKGROUND: Zagotenemab (LY3303560), a monoclonal antibody, preferentially binds to extracellular, misfolded, aggregated tau that has been implicated in Alzheimer’s disease (AD). OBJECTIVE: The goal of this study was to assess the safety and pharmacokinetics of multiple doses of zagotenemab in parti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Willis, Brian A., Lo, Albert C., Dage, Jeffrey L., Shcherbinin, Sergey, Chinchen, Louise, Andersen, Scott W., LaBell, Elizabeth S., Perahia, David G.S., Hauck, Paula M., Lowe, Stephen L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2023
Materias:	Research Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578324/ https://www.ncbi.nlm.nih.gov/pubmed/37849628 http://dx.doi.org/10.3233/ADR-230012

Ejemplares similares

Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimer’s Disease
por: Abyadeh, Morteza, et al.
Publicado: (2021)

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial
por: Pontecorvo, Michael J., et al.
Publicado: (2022)

Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
por: Humeniuk, Rita, et al.
Publicado: (2023)

Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog(®) Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
por: Leohr, Jennifer, et al.
Publicado: (2021)

A Pharmacokinetic, Safety, and Tolerability Trial of Palovarotene in Healthy Japanese and Non-Japanese Participants
por: Dube, Louise, et al.
Publicado: (2023)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Patients with Type 2 Diabetes Mellitus: A Phase I Randomised, Crossover Study
por: Leohr, Jennifer, et al.
Publicado: (2020)

Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID‐19
por: Pfeifer, Nathan D., et al.
Publicado: (2021)

Pharmacokinetic, Safety, and Tolerability Evaluations of Gepotidacin (GSK2140944) in Healthy Japanese Participants
por: Barth, Aline, et al.
Publicado: (2022)

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer's disease
por: Zimmer, Jennifer A., et al.
Publicado: (2021)

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial
por: Shcherbinin, Sergey, et al.
Publicado: (2022)

Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog(®) (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of GSK3772847 in healthy participants
por: Pefani, Eleni, et al.
Publicado: (2023)

Donanemab (LY3002813) dose‐escalation study in Alzheimer's disease
por: Lowe, Stephen Loucian, et al.
Publicado: (2021)

Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants
por: Iwamoto, Marian, et al.
Publicado: (2023)

Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer’s Disease Dementia
por: Lo, Albert C., et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
por: Lo, Arthur, et al.
Publicado: (2021)

Pharmacokinetic Interactions and Tolerability of Rosuvastatin and Ezetimibe: A Randomized, Phase 1, Crossover Study in Healthy Chinese Participants
por: Wang, Lu, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Benralizumab: A Phase 1, Randomized, Single-Blind Study of Healthy Chinese Participants
por: Cheung, Tommy Tsang, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants
por: Maden, Charlotte H., et al.
Publicado: (2018)

A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK‐041 in healthy participants and patients with stable schizophrenia
por: Yin, Wei, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
por: Robinson, Philip, et al.
Publicado: (2023)

An open‐label, dose‐escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
por: Simon, Marc A., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants
por: Holze, Friederike, et al.
Publicado: (2020)

Bioequivalence of Ultra Rapid Lispro (URLi) U100 and U200 Formulations in Healthy Subjects
por: Linnebjerg, Helle, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants
por: Singh, Rajendra P., et al.
Publicado: (2021)

Pharmacokinetics, safety, and tolerability of BMS‐986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment
por: Qosa, Hisham, et al.
Publicado: (2023)

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment
por: Granhall, Charlotte, et al.
Publicado: (2018)

Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis
por: Hunter, David J, et al.
Publicado: (2010)

Pharmacokinetics and safety of dexlansoprazole MR in pediatric patients with symptomatic gastroesophageal reflux disease
por: Kukulka, Michael, et al.
Publicado: (2014)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Pharmacokinetics/Pharmacodynamics and tolerability of cefiderocol in the clinical setting
por: Perea, José Ramón Azanza, et al.
Publicado: (2022)

Hybrid treatment of symptomatic carotid disease
por: Lowe, Christopher, et al.
Publicado: (2019)

A Phase 1 first‐in‐human study of the safety, tolerability, and pharmacokinetics of the ROBO2 fusion protein PF‐06730512 in healthy participants
por: Lim, Chay Ngee, et al.
Publicado: (2021)

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Mirogabalin in Healthy Chinese Participants: A Randomized, Double-Blind, Placebo-Controlled Study
por: Li, Yi, et al.
Publicado: (2023)

Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants
por: Wang, Le-le, et al.
Publicado: (2022)

Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants
por: Perera, Vidya, et al.
Publicado: (2022)

The Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide 400 μg Administered by Inhalation as Single and Multiple (Twice Daily) Doses in Healthy Chinese Participants
por: Li, Weimin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7vgp25lm4kjb0lasbrdnvsrset